X4 Pharmaceuticals (Nasdaq:XFOR) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

XFOR 주식 개요

후기 단계의 임상 바이오 제약 회사인 X4 제약은 희귀 질환 치료를 위한 새로운 치료제의 연구, 개발 및 상용화에 주력하고 있습니다.

XFOR 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	3/6
과거 실적	2/6
재무 상태	3/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 91.3% 에서 거래

수익은 연간 48.73% 증가할 것으로 예상됩니다.

올해부터 흑자전환

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

수익은 향후 3년간 연평균 16.5% 씩 감소할 것으로 예상됩니다.

수익이 1백만 달러 미만인 경우 ( $0 )

재무 결과에 영향을 미치는 대규모 일회성 항목

지난 1년 동안 주주가 희석되었습니다.

+ 1 더 많은 위험

X4 Pharmaceuticals, Inc. 경쟁사

Fennec Pharmaceuticals

NasdaqCM:FENC

US$140.6m

Entrada Therapeutics

NasdaqGM:TRDA

US$554.9m

Spero Therapeutics

NasdaqGS:SPRO

US$69.2m

POINT Biopharma Global

NasdaqCM:PNT

US$1.3b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 X4 Pharmaceuticals
과거 주가
현재 주가	US$0.66
52주 최고치	US$1.60
52주 최저치	US$0.53
베타	0.36
11개월 변경	-5.07%
3개월 변경 사항	12.93%
1년 변경 사항	-39.91%
33년 변화	-87.28%
5년 변화	-94.75%
IPO 이후 변화	-95.69%

최근 뉴스 및 업데이트

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jul 02

Recent updates

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22

X4 Pharmaceuticals EPS misses by $0.44

May 06

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

Mar 16

X4 Pharmaceuticals EPS misses by $0.12

Nov 05

주주 수익률

	XFOR	US Biotechs	US 마켓
7D	-7.4%	-3.0%	0.9%
1Y	-39.9%	19.2%	32.4%

수익률 대 산업: XFOR 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: XFOR 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is XFOR's price volatile compared to industry and market?
XFOR volatility
XFOR Average Weekly Movement	10.7%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

안정적인 주가: XFOR 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: XFOR 의 주간 변동성( 14% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
n/a	127	Paula Ragan	www.x4pharma.com

후기 단계의 임상 바이오 제약 회사인 X4 제약은 희귀 질환 치료를 위한 새로운 치료제의 연구, 개발 및 상용화에 주력하고 있습니다. 주요 제품 후보로는 사마귀, 저감마글로불린혈증, 감염, 골수괴사증후군 환자 치료를 위한 임상 3상 시험과 선천성, 특발성 또는 주기적 호중구 감소증 치료를 위한 임상 2상 시험을 진행 중인 케모카인 수용체 C-X-C 케모카인 수용체 4형(CXCR4)의 소분자 억제제인 마보릭사포(mavorixafor)가 있다. 또한 CXCR4 의존성 질환 및 원발성 면역 결핍증 치료를 위한 CXCR4 길항제인 X4P-003과 혈액뇌장벽 질환 치료를 위한 CXCR4 길항제인 X4P-002를 개발 중입니다.

X4 Pharmaceuticals, Inc. 기본 사항 요약

X4 Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
XFOR 기본 통계
시가총액	US$111.21m
수익(TTM)	US$17.63m
수익(TTM)	US$563.00k

6.3x

P/E 비율

196.0x

P/S 비율

XFOR 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
XFOR 손익 계산서(TTM)
수익	US$563.00k
수익 비용	US$268.00k
총 이익	US$295.00k
기타 비용	-US$17.34m
수익	US$17.63m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	0.10
총 마진	52.40%
순이익 마진	3,131.79%
부채/자본 비율	79.4%

XFOR 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

XFOR 주식 개요

보상

위험 분석

X4 Pharmaceuticals, Inc. 경쟁사

NasdaqCM:FENC

US$140.6m

NasdaqGM:TRDA

US$554.9m

NasdaqGS:SPRO

US$69.2m

NasdaqCM:PNT

US$1.3b

가격 내역 및 성능

최근 뉴스 및 업데이트

X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

New major risk - Revenue and earnings growth

X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial

Recent updates

X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

New major risk - Revenue and earnings growth

X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial

New major risk - Financial position

X4 Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates increase by 12%

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome

Price target increased by 8.7% to US$3.55

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Price target increased by 13% to US$3.65

X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 8.9% to US$3.20

X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule

CFO, Treasurer & Corporate Secretary notifies of intention to sell stock

X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome

Director recently sold US$138k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding

X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target increased by 7.5% to US$3.76

X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Price target decreased by 9.5% to US$4.07

Price target decreased by 12% to US$4.21

Consensus revenue estimates fall by 11%

Price target decreased to US$5.08

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Price target increased to US$5.90

X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals: Upcoming Catalysts

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

X4 Pharmaceuticals, Inc. Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

X4 Pharmaceuticals, Inc. announced that it expects to receive $55.763275 million in funding from New Enterprise Associates, Inc., Acorn Bioventures, Lumira Ventures, Bain Capital Life Sciences Investors, LLC, OrbiMed Advisors LLC, Hercules Capital, Inc.

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Price target decreased to US$12.36

X4 Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$13.57

Consensus forecasts updated

Price target decreased to US$15.43

X4 Pharmaceuticals, Inc. Presents New Clinical and Scientific Data At 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

Price target decreased to US$18.00

X4 Pharmaceuticals, Inc. Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

Founder notifies of intention to sell stock

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Founder notifies of intention to sell stock